Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.52
ABBV's Cash to Debt is ranked lower than
60% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.03 vs. ABBV: 0.52 )
Ranked among companies with meaningful Cash to Debt only.
ABBV' s 10-Year Cash to Debt Range
Min: 0.5   Max: No Debt
Current: 0.52

Equity to Asset 0.05
ABBV's Equity to Asset is ranked lower than
64% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.43 vs. ABBV: 0.05 )
Ranked among companies with meaningful Equity to Asset only.
ABBV' s 10-Year Equity to Asset Range
Min: -0.01   Max: 0.69
Current: 0.05

-0.01
0.69
Interest Coverage 7.95
ABBV's Interest Coverage is ranked higher than
65% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. ABBV: 7.95 )
Ranked among companies with meaningful Interest Coverage only.
ABBV' s 10-Year Interest Coverage Range
Min: 7.95   Max: 9999.99
Current: 7.95

7.95
9999.99
F-Score: 7
Z-Score: 3.84
M-Score: -2.93
WACC vs ROIC
12.96%
28.63%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 18.33
ABBV's Operating margin (%) is ranked higher than
84% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.69 vs. ABBV: 18.33 )
Ranked among companies with meaningful Operating margin (%) only.
ABBV' s 10-Year Operating margin (%) Range
Min: 17.09   Max: 34.7
Current: 18.33

17.09
34.7
Net-margin (%) 8.89
ABBV's Net-margin (%) is ranked higher than
71% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.76 vs. ABBV: 8.89 )
Ranked among companies with meaningful Net-margin (%) only.
ABBV' s 10-Year Net-margin (%) Range
Min: 8.89   Max: 32.62
Current: 8.89

8.89
32.62
ROE (%) 51.36
ABBV's ROE (%) is ranked higher than
97% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.48 vs. ABBV: 51.36 )
Ranked among companies with meaningful ROE (%) only.
ABBV' s 10-Year ROE (%) Range
Min: 24.85   Max: 199.32
Current: 51.36

24.85
199.32
ROA (%) 6.47
ABBV's ROA (%) is ranked higher than
71% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. ABBV: 6.47 )
Ranked among companies with meaningful ROA (%) only.
ABBV' s 10-Year ROA (%) Range
Min: 6.25   Max: 39.54
Current: 6.47

6.25
39.54
ROC (Joel Greenblatt) (%) 89.63
ABBV's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.04 vs. ABBV: 89.63 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ABBV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 74.12   Max: 169.72
Current: 89.63

74.12
169.72
Revenue Growth (3Y)(%) 3.90
ABBV's Revenue Growth (3Y)(%) is ranked higher than
63% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -5.40 vs. ABBV: 3.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ABBV' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 3.9
Current: 3.9

0
3.9
EBITDA Growth (3Y)(%) -10.70
ABBV's EBITDA Growth (3Y)(%) is ranked higher than
59% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -31.90 vs. ABBV: -10.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ABBV' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -10.7
Current: -10.7

EPS Growth (3Y)(%) -20.40
ABBV's EPS Growth (3Y)(%) is ranked higher than
59% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -53.60 vs. ABBV: -20.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ABBV' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: -20.4
Current: -20.4

» ABBV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ABBV Guru Trades in Q2 2014

NWQ Managers 83,878 sh (New)
Paul Tudor Jones 257,344 sh (New)
Lee Ainslie 3,235,133 sh (New)
Louis Moore Bacon 185,000 sh (New)
Jana Partners 75,000 sh (New)
Ken Fisher 1,104,609 sh (+76.13%)
Manning & Napier Advisors, Inc 192,029 sh (+31.46%)
Westport Asset Management 180,000 sh (unchged)
Tom Russo 86,777 sh (unchged)
Robert Bruce 231,300 sh (unchged)
Jeremy Grantham Sold Out
Dodge & Cox 36,649 sh (-0.14%)
PRIMECAP Management 6,304,122 sh (-0.50%)
Mario Gabelli 10,382 sh (-0.76%)
John Hussman 300,000 sh (-1.07%)
Pioneer Investments 2,014,581 sh (-1.52%)
Murray Stahl 35,273 sh (-1.70%)
Bill Frels 264,316 sh (-2.08%)
Jeff Auxier 73,421 sh (-6.40%)
Jim Simons 2,233,600 sh (-20.14%)
George Soros 150,000 sh (-57.14%)
Joel Greenblatt 88,923 sh (-61.19%)
» More
Q3 2014

ABBV Guru Trades in Q3 2014

John Paulson 13,000,000 sh (New)
Steve Mandel 5,247,201 sh (New)
Steven Cohen 184,300 sh (New)
Andreas Halvorsen 10,769,105 sh (New)
George Soros 1,537,146 sh (+924.76%)
Lee Ainslie 4,723,578 sh (+46.01%)
Jana Partners 100,000 sh (+33.33%)
Dodge & Cox 38,849 sh (+6.00%)
NWQ Managers 85,948 sh (+2.47%)
PRIMECAP Management 6,454,836 sh (+2.39%)
Paul Tudor Jones 261,700 sh (+1.69%)
Westport Asset Management 180,000 sh (unchged)
Mario Gabelli 10,382 sh (unchged)
Pioneer Investments 2,601,836 sh (unchged)
Tom Russo 86,777 sh (unchged)
Robert Bruce 231,300 sh (unchged)
Murray Stahl 35,265 sh (-0.02%)
Bill Frels 263,837 sh (-0.18%)
Manning & Napier Advisors, Inc 186,088 sh (-3.09%)
Ken Fisher 999,768 sh (-9.49%)
Louis Moore Bacon 80,000 sh (-56.76%)
Jeff Auxier 27,371 sh (-62.72%)
John Hussman 100,000 sh (-66.67%)
Jim Simons 722,355 sh (-67.66%)
Joel Greenblatt 9,460 sh (-89.36%)
» More
Q4 2014

ABBV Guru Trades in Q4 2014

First Eagle Investment 1,016,097 sh (New)
Mario Gabelli 34,557 sh (+232.85%)
Pioneer Investments 3,102,193 sh (+19.23%)
NWQ Managers 96,015 sh (+11.71%)
PRIMECAP Management 6,578,886 sh (+1.92%)
Bill Frels 267,837 sh (+1.52%)
Manning & Napier Advisors, Inc 187,451 sh (+0.73%)
Robert Bruce 232,915 sh (+0.70%)
Ken Fisher 1,001,105 sh (+0.13%)
Westport Asset Management 180,000 sh (unchged)
John Hussman 100,000 sh (unchged)
George Soros Sold Out
Andreas Halvorsen Sold Out
Jana Partners Sold Out
John Paulson Sold Out
Lee Ainslie Sold Out
Steve Mandel Sold Out
Steven Cohen Sold Out
Tom Russo 86,718 sh (-0.07%)
Murray Stahl 35,158 sh (-0.30%)
Jeff Auxier 27,071 sh (-1.10%)
Dodge & Cox 38,055 sh (-2.04%)
Joel Greenblatt 8,759 sh (-7.41%)
Louis Moore Bacon 30,044 sh (-62.45%)
Jim Simons 217,900 sh (-69.83%)
Paul Tudor Jones 12,914 sh (-95.07%)
» More
Q1 2015

ABBV Guru Trades in Q1 2015

Larry Robbins 2,443,632 sh (New)
Lee Ainslie 4,320 sh (New)
Scott Black 119,485 sh (New)
Steven Cohen 144,800 sh (New)
David Dreman 9,655 sh (New)
Joel Greenblatt 555,223 sh (+6238.89%)
NWQ Managers 1,839,012 sh (+1815.34%)
Jim Simons 1,188,397 sh (+445.39%)
Mario Gabelli 47,212 sh (+36.62%)
Bill Frels 272,026 sh (+1.56%)
Ken Fisher 1,010,756 sh (+0.96%)
Robert Bruce 232,915 sh (unchged)
Westport Asset Management 180,000 sh (unchged)
Louis Moore Bacon 250,000 sh (unchged)
Tom Russo 86,718 sh (unchged)
John Hussman Sold Out
Louis Moore Bacon Sold Out
First Eagle Investment Sold Out
Manning & Napier Advisors, Inc 187,414 sh (-0.02%)
Dodge & Cox 35,055 sh (-7.88%)
Murray Stahl 32,064 sh (-8.80%)
Paul Tudor Jones 10,070 sh (-22.02%)
Pioneer Investments 2,368,141 sh (-23.66%)
Jeff Auxier 19,471 sh (-28.07%)
PRIMECAP Management 3,730,836 sh (-43.29%)
» More
» Details

Insider Trades

Latest Guru Trades with ABBV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on AbbVie Inc

Lountzis Asset Management Comments on Abbvie - Mar 21, 2014

ABBVIE (ABBV), spun off from Abbott, represents their research-based proprietary pharmaceutical business and is led by its highly profitable Humira franchise. Humira makes up approximately 50% of revenues and over 70% of profits. While AbbVie is focused on growing its pipeline, the reality is Humira, the leading rheumatoid arthritis drug, will continue to drive the revenue and profit growth for AbbVie until some of the experimental drugs they are working on such as its Hepatitis C virus drug gains FDA approval and enters the market. As a result, we are reviewing our holding of AbbVie at this time given its enormous concentration on one drug. While it continues to lead in many areas and it continues to grow around the world, it remains a concern for us. AbbVie’s revenues in 2013 exceeded $18.8 billion with operating earnings of $5.7 billion.



From Lountzis Asset Management 2013 Annual Letter



Check out latest stock trades

Top Ranked Articles about AbbVie Inc

John Paulson's Top 5 New Holdings For Q3
John Paulson (Trades, Portfolio)’s hedge fund Paulson & Co. was founded in 1994 and has $22.8 billion in assets under management as of Jul 2014. The fund focuses primarily on event-driven arbitrage situations. Paulson’s top strategies, the Advantage and Advantage Plus funds, lost 4.8 percent and 3.9 percent this year through August, the New York Times reported. Read more...
The 5 Most-Owned Spin-Offs of Investment Gurus
Numerous financiers, including Joel Greenblatt (Trades, Portfolio), have posited that investors can beat the market by investing in spin-offs – small portions of larger companies separated to stand as their own, independent company. But is this true? This is a question that GuruFocus writer Vera Yuan pondered in her article, “Can Spin-Offs Beat the Market?” Her research concluded that 52 weeks after being spun off, all spun-off companies since 2009 collectively outperformed the market by 84.28%. For this reason, GuruFocus introduced the “Spin-Off List” screener, which tracks all companies spun off since 2013. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 60.90
ABBV's P/E(ttm) is ranked lower than
79% of the 461 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.10 vs. ABBV: 60.90 )
Ranked among companies with meaningful P/E(ttm) only.
ABBV' s 10-Year P/E(ttm) Range
Min: 9.86   Max: 63.84
Current: 60.9

9.86
63.84
Forward P/E 12.84
ABBV's Forward P/E is ranked higher than
79% of the 266 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.66 vs. ABBV: 12.84 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 58.50
ABBV's PE(NRI) is ranked lower than
69% of the 461 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.70 vs. ABBV: 58.50 )
Ranked among companies with meaningful PE(NRI) only.
ABBV' s 10-Year PE(NRI) Range
Min: 9.85   Max: 63.95
Current: 58.5

9.85
63.95
P/B 78.60
ABBV's P/B is ranked lower than
126% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. ABBV: 78.60 )
Ranked among companies with meaningful P/B only.
ABBV' s 10-Year P/B Range
Min: 15.75   Max: 76.9
Current: 78.6

15.75
76.9
P/S 5.30
ABBV's P/S is ranked lower than
83% of the 637 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. ABBV: 5.30 )
Ranked among companies with meaningful P/S only.
ABBV' s 10-Year P/S Range
Min: 2.83   Max: 5.68
Current: 5.3

2.83
5.68
PFCF 28.20
ABBV's PFCF is ranked higher than
50% of the 326 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.50 vs. ABBV: 28.20 )
Ranked among companies with meaningful PFCF only.
ABBV' s 10-Year PFCF Range
Min: 8.64   Max: 38.09
Current: 28.2

8.64
38.09
POCF 23.30
ABBV's POCF is ranked higher than
56% of the 445 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.56 vs. ABBV: 23.30 )
Ranked among companies with meaningful POCF only.
ABBV' s 10-Year POCF Range
Min: 8.19   Max: 31.54
Current: 23.3

8.19
31.54
EV-to-EBIT 28.73
ABBV's EV-to-EBIT is ranked lower than
54% of the 472 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.75 vs. ABBV: 28.73 )
Ranked among companies with meaningful EV-to-EBIT only.
ABBV' s 10-Year EV-to-EBIT Range
Min: 10.3   Max: 33.7
Current: 28.73

10.3
33.7
Current Ratio 1.39
ABBV's Current Ratio is ranked lower than
75% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.37 vs. ABBV: 1.39 )
Ranked among companies with meaningful Current Ratio only.
ABBV' s 10-Year Current Ratio Range
Min: 1.22   Max: 2.82
Current: 1.39

1.22
2.82
Quick Ratio 1.30
ABBV's Quick Ratio is ranked lower than
65% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.72 vs. ABBV: 1.30 )
Ranked among companies with meaningful Quick Ratio only.
ABBV' s 10-Year Quick Ratio Range
Min: 1.06   Max: 2.65
Current: 1.3

1.06
2.65
Days Inventory 90.75
ABBV's Days Inventory is ranked higher than
61% of the 609 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.49 vs. ABBV: 90.75 )
Ranked among companies with meaningful Days Inventory only.
ABBV' s 10-Year Days Inventory Range
Min: 35.55   Max: 93.77
Current: 90.75

35.55
93.77
Days Sales Outstanding 77.80
ABBV's Days Sales Outstanding is ranked lower than
55% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.43 vs. ABBV: 77.80 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABBV' s 10-Year Days Sales Outstanding Range
Min: 78.47   Max: 93.3
Current: 77.8

78.47
93.3

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.70
ABBV's Dividend Yield is ranked higher than
75% of the 405 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. ABBV: 2.70 )
Ranked among companies with meaningful Dividend Yield only.
ABBV' s 10-Year Dividend Yield Range
Min: 0.85   Max: 3.44
Current: 2.7

0.85
3.44
Dividend Payout 1.55
ABBV's Dividend Payout is ranked lower than
113% of the 340 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. ABBV: 1.55 )
Ranked among companies with meaningful Dividend Payout only.
ABBV' s 10-Year Dividend Payout Range
Min: 0.57   Max: 1.36
Current: 1.55

0.57
1.36
Yield on cost (5-Year) 2.80
ABBV's Yield on cost (5-Year) is ranked higher than
60% of the 410 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.48 vs. ABBV: 2.80 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ABBV' s 10-Year Yield on cost (5-Year) Range
Min: 0.85   Max: 3.44
Current: 2.8

0.85
3.44
Share Buyback Rate -0.70
ABBV's Share Buyback Rate is ranked higher than
59% of the 410 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -2.40 vs. ABBV: -0.70 )
Ranked among companies with meaningful Share Buyback Rate only.
ABBV' s 10-Year Share Buyback Rate Range
Min: 0   Max: -0.7
Current: -0.7

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.20
ABBV's Price/Median PS Value is ranked higher than
52% of the 615 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. ABBV: 1.20 )
Ranked among companies with meaningful Price/Median PS Value only.
ABBV' s 10-Year Price/Median PS Value Range
Min: 0.67   Max: 1.21
Current: 1.2

0.67
1.21
Earnings Yield (Greenblatt) 3.50
ABBV's Earnings Yield (Greenblatt) is ranked higher than
56% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.60 vs. ABBV: 3.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
ABBV' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3   Max: 9.7
Current: 3.5

3
9.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:ABBV.Switzerland, ABBV.France, 4AB.Germany, 0QCV.UK, ABBV.Mexico,
AbbVie Inc was incorporated in Delaware on April 10, 2012, and is a wholly owned subsidiary of Abbott. The company is a research-based biopharmaceutical company with portfolio of proprietary products including a broad line of adult and pediatric pharmaceuticals. The company discovers, develops, manufactures and sells proprietary pharmaceutical products. Its products are used to treat diseases including rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis complications. AbbVie also has a pipeline of new medicines, including more than 20 compounds or indications in Phase II or Phase III development across such important medical specialties as immunology, renal care, hepatitis C, women's health, oncology, and neuroscience, including multiple sclerosis and Alzheimer's disease. AbbVie operates in one business segment—pharmaceutical products. AbbVie competes with other research-based pharmaceuticals and biotechnology companies that discover, manufacture, market, and sell proprietary pharmaceutical products and biologics.
» More Articles for ABBV

Headlines

Articles On GuruFocus.com
Abbvie Inc. Dividend Stock Analysis May 26 2015 
Scott Black's Most Heavily Weighted Trades In Q1 2015 May 21 2015 
Risk & Reward with Gilead Sciences Inc. (GILD) May 14 2015 
8 Top Healthcare Stocks to Watch May 13 2015 
AbbVie Floats Mega-Bond Deal For Acquisition Funding May 08 2015 
Pharmacyclics Posts A Mixed First Quarter Ahead Of Being Acquired By AbbVie May 07 2015 
AbbVie Focusing On Diversification Routes To Put Higher Sales Numbers On The Board Apr 24 2015 
Analyzing Chris Davis' Top Holdings Apr 14 2015 
Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
AbbVie Strikes The Biggest Deal For Treatment Of Cancer Mar 10 2015 

More From Other Websites
AbbVie Is Buying Back $5 Billion in Stock. Hurray? May 27 2015
AbbVie (ABBV) Stock Gains on Bullish JPMorgan Note May 27 2015
JPMorgan: Buy AbbVie, Low Valuation Belies EPS Growth Potential May 27 2015
AbbVie Accelerates Share Buybacks May 27 2015
ABBVIE INC. Files SEC form 8-K, Other Events May 27 2015
AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and... May 26 2015
Enanta Announces SVR12 results of 95% from AbbVie’s GIFT-1 Study in Non-cirrhotic, Japanese... May 26 2015
AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and... May 26 2015
NWQ's First-Quarter Buys and Adds Affect Portfolio May 26 2015
Ambarella Leads 3 Top Stocks Bucking The Sell-Off May 26 2015
Jim Cramer -- Here's Why I'm Buy, Buy, Buying J&J and Selling Merck May 26 2015
This Medical Stock Refuses To Fall With Major Stock Indexes May 26 2015
AbbVie (ABBV) Stock Gains After Completing $21 Billion Pharmacyclics Purchase May 26 2015
Abbvie completes $21 billion buyout of Pharmacyclics May 26 2015
Abbvie completes $21 billion buyout of Pharmacyclics May 26 2015
ABBVIE INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Other Events,... May 26 2015
AbbVie Completes Acquisition of Pharmacyclics May 26 2015
8:33 am AbbVie closes Pharmacyclics (PCYC) acquisition;... May 26 2015
AbbVie Completes Acquisition of Pharmacyclics May 26 2015
AbbVie Announces Expiration of Hart-Scott-Rodino Waiting Period for AbbVie's Acquisition of... May 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK